BioSpace News Archive

Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial public offering of shares of its common stock. Gain is offering 3,636,364 shares of its common stock. The initial public offering price is expected to be between $10.00 and $12.00 per share, before underwriting discounts and commissions.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that CEO Faz Chowdhury, Ph.D. will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-18, 2021.

- New Initiative is part of I-Mab’s long-term strategy to drive innovation and scientific leadership in immuno-oncology - New collaborations signed will allow I-Mab access to cutting edge technology platforms to develop novel drug molecules - I-Mab continues to focus on delivering on key clinical programs while building pipeline of next generation assets

Hollister Incorporated, an independent, employee-owned company that develops, manufactures, and markets healthcare products worldwide has launched the Infyna Chic™ intermittent catheter, the latest in the company’s line of hydrophilic catheter products, to the US market.

DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence subject enrollment in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002).

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that the Company’s fourth quarter and full year 2020 financial results will be released after market close on Monday, March 22, 2021

Pivotal Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Chemotherapy in Patients with Advanced Endometrial Cancer to be Presented During Plenary Session Additional Plenary Session to Include Investigational Data on Farletuzumab Combination with Carboplatin in Patients with Low CA125 Platinum-Sensitive Ovarian Cancer

Impact Therapeutics announced today that the first patient was recently dosed in the first-in-human Phase 1 clinical study of Wee1 Inhibitor IMP7068 in the United States . This is a Phase 1, open-label, multi-center, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity

Secured multi-year commitments for majority of blood plasma supply and production output Catalyst Capital commits additional funding to support accelerated path to market Builds on momentum following appointment of CEO and completion of Phase III clinical trials for PlasmaCap IG (Intravenous Immunoglobulin or “IVIG”)

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Oppenheimer 31 st Annual Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Wednesday, March 17, 2021, at 10:00 a.m. Eastern Time.